Literature DB >> 12668216

Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II.

Kazuhiro Takahashi1, Kazuhito Totsune, Osamu Murakami, Zenei Arihara, Takao Noshiro, Yutaka Hayashi, Shigeki Shibahara.   

Abstract

Urotensin II is a potent vasoactive peptide, which was originally isolated from fish urophysis. We studied expression of urotensin II and its receptor mRNAs in the tumor tissues of adrenocortical tumors, pheochromocytomas and neuroblastomas. Effects of exogenously added urotensin II on cell proliferation were studied in a human adrenocortical carcinoma cell line, SW-13 and a human renal cell carcinoma cell line, VMRC-RCW. The reverse transcriptase polymerase chain reaction (RT-PCR) showed expression of urotensin II and its receptor mRNAs in all the samples examined; seven pheochromocytomas, nine adrenocortical adenomas (four with primary aldosteronism, four with Cushing syndrome and one with non-functioning adenoma), four adrenocortical carcinomas, one ganglioneuroblastoma and five neuroblastomas, as well as four normal portions of adrenal glands (cortex and medulla). Urotensin II-like immunoreactivity was detected in one of eight adrenocortical adenomas, two of four adrenocortical carcinomas, one of six pheochromocytomas, and one of five neuroblastomas by radioimmunoassay, but not in normal portions of adrenal glands (detection limit; 0.2pmol/g wet weight). Treatment with urotensin II for 24h significantly increased number of SW-13 cells (at 10(-8) and 10(-7)mol/l) and VMRC-RCW cells (at 10(-8)mol/l). These findings raise the possibility that urotensin II may act as an autocrine/paracrine growth stimulating factor in adrenal tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12668216     DOI: 10.1016/s0196-9781(03)00039-1

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  17 in total

1.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

2.  Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.

Authors:  Kazuhiro Takahashi; Itaru Shoji; Akiko Shibasaki; Ichiro Kato; Keisuke Hiraishi; Hajime Yamamoto; Kiriko Kaneko; Osamu Murakami; Ryo Morimoto; Fumitoshi Satoh; Sadayoshi Ito; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2009-11-07       Impact factor: 3.444

3.  Urantide improves the structure and function of right ventricle as determined by echocardiography in monocrotaline-induced pulmonary hypertension rat model.

Authors:  Yan Wang; Wei Tian; Chunhong Xiu; Ming Yan; Shuya Wang; Yifang Mei
Journal:  Clin Rheumatol       Date:  2018-01-23       Impact factor: 2.980

4.  Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.

Authors:  C Lecointre; L Desrues; J E Joubert; N Perzo; P-O Guichet; V Le Joncour; C Brulé; M Chabbert; R Leduc; L Prézeau; A Laquerrière; F Proust; P Gandolfo; F Morin; H Castel
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

5.  The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.

Authors:  Onder Yumrutas; Serdar Oztuzcu; Hakan Büyükhatipoglu; Ibrahim Bozgeyik; Esra Bozgeyik; Yusuf Ziya Igci; Haydar Bagis; M Ozgur Cevik; M Emin Kalender; Zeynep Eslik; Ahmet Arslan
Journal:  Tumour Biol       Date:  2015-01-22

6.  Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.

Authors:  Ottavio De Cobelli; Carlo Buonerba; Daniela Terracciano; Danilo Bottero; Giuseppe Lucarelli; Pierluigi Bove; Vincenzo Altieri; Ioman Coman; Sisto Perdonà; Gaetano Facchini; Massimiliano Berretta; Giuseppe Di Lorenzo; Paolo Grieco; Ettore Novellino; Renato Franco; Michele Caraglia; Claudia Manini; Vincenzo Mirone; Sabino De Placido; Guru Sonpavde; Matteo Ferro
Journal:  Future Oncol       Date:  2015-09-18       Impact factor: 3.404

7.  The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.

Authors:  Ozan Balakan; Mehmet Emin Kalender; Ali Suner; Beyhan Cengiz; Serdar Oztuzcu; Recep Bayraktar; Ersin Borazan; Taner Babacan; Celaletdin Camci
Journal:  Med Sci Monit       Date:  2014-08-12

8.  Urotensin-II: More Than a Mediator for Kidney.

Authors:  Ayşe Balat; Mithat Büyükçelik
Journal:  Int J Nephrol       Date:  2012-10-10

9.  Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.

Authors:  Renato Franco; Silvia Zappavigna; Vincenzo Gigantino; Amalia Luce; Monica Cantile; Margherita Cerrone; Gaetano Facchini; Sisto Perdonà; Sandro Pignata; Giuseppe Di Lorenzo; Sergio Chieffi; Giovanni Vitale; Marco De Sio; Alessandro Sgambato; Gerardo Botti; Ali Munaim Yousif; Ettore Novellino; Paolo Grieco; Michele Caraglia
Journal:  J Exp Clin Cancer Res       Date:  2014-06-03

10.  Urotensin-II-Mediated Reactive Oxygen Species Generation via NADPH Oxidase Pathway Contributes to Hepatic Oval Cell Proliferation.

Authors:  XiaoTong Yu; PengYan Wang; ZhengMing Shi; Kun Dong; Ping Feng; HongXia Wang; XueJiang Wang
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.